SCSophia Cichutek

Sophia Cichutek

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sophia Cichutek has a total of 39 co-authors. Here are the top co-authors by number of shared publications:

  • Walter Fiedler

    Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, Hubertus Wald University Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

    2 shared publications
  • Alessa Zoe Schaffrath

    Research Department Cell and Gene Therapy, Department of Stem Cell Transplantation University Medical Center Hamburg‐Eppendorf (UKE) Hamburg Germany

    1 shared publication
  • Anna Josephine Gebhardt

    Institute of Immunology University Medical Center Hamburg‐Eppendorf (UKE) Hamburg Germany

    1 shared publication
  • Ansgar W. Lohse

    I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

    1 shared publication
  • Boris Fehse

    Research Department Cell and Gene Therapy, Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany

    1 shared publication
  • Carsten Bokemeyer

    Department of Oncology, Hematology and Bone Marrow Transplantation With Section Pneumonology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

    1 shared publication

Latest Publications

  • Open Access

    FGL-1 plasma levels correlate with markers of inflammation and severe disease during SARS-CoV-2 infection

    by Sophia Cichutek, Leon Cords, Kilian Keetz, Marissa Herrmann, Liz J. Lam, Maria Mader, Robin Woost, Stefan Schmiedel, Ansgar W. Lohse, Carsten Bokemeyer, et al.

    Background: Fibrinogen-like protein 1 (FGL-1), primarily secreted by the liver, modulates immune responses and is upregulated in patients with hepatocellular carcinoma. FGL-1 affects T-cell function by interacting with lymphocyte-activation gene 3 (LAG-3), and blocking this interaction can enhance T-cell activity, making it a potential therapeutic target. In coronavirus disease 2019 (COVID-19), the upregulation of immune checkpoints on T cells, particularly LAG-3, is associated with disease severity. Liver inflammation and damage are well-known features of COVID-19 pathogenesis; however, little is known about FGL-1 expression patterns in COVID-19 and other infectious diseases. Methods: In a cohort of 65 patients with COVID-19 and 33 healthy donors, plasma FGL-1 levels were measured, and their correlations with clinical parameters and the course of the disease were evaluated. Additionally, both bulk and severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2)-specific T-cell immune phenotypes, as well as SARS-CoV-2-specific immune responses were comprehensively characterized and measured using multicolor flow cytometry and pMHC multimer technology. Results: Plasma FGL-1 levels were elevated in patients with COVID-19 and correlated with IL-6 and disease severity. LAG-3 was significantly upregulated on bulk and COVID-19-specific CD8 + T cells and was co-expressed with T-cell activation markers (CD38, HLA-DR) and inhibitory receptors (PD-1, TIGIT). Conclusion: These findings suggest a role for FGL-1 in the pathogenesis of COVID-19, potentially through modulation of T-cell activation and function via LAG-3, and may also be relevant in other hyperinflammatory conditions where immune modulation plays a role.

  • Open Access

    Novel Bispecific Engagers Targeting the CεmX Domain of mIgE ‐Expressing Cells

    by Constantin Möller, Julia Hambach, Alessa Zoe Schaffrath, Thomas Eden, Sophia Cichutek, Anna Josephine Gebhardt, Natalie Tode, Ronald Maitschke‐Rajasekharan, Philipp Lewe, Sharon Qi, et al.

    Background: IgE‐associated allergic diseases, affecting approximately 30% of the global population, are a major health burden. Standard treatments, including pharmacotherapy and allergen immunotherapy (AIT), have limitations such as adverse effects, insufficient symptom relief and long treatment durations. Methods: In this study, we developed and evaluated a bispecific T‐cell engager (TCE) and a half‐life extended (HLE) bispecific natural killer (NK) cell engager (NKCE) targeting IgE‐producing cells, to offer novel, potentially curative therapeutic options. The TCE and HLE‐NKCE constructs were designed to target the CεmX domain of membrane‐bound IgE (mIgE) and engage T cells and NK cells, respectively. Their efficacy was assessed through in vitro luciferase‐based cytotoxicity assays using Ramos and U266 B‐cell lines expressing mIgE as target cells, and primary human immune effector cells and the NK‐cell line NK‐92 as effector cells. Additional characterisation of the constructs was performed using flow cytometry. Results: Both TCE and HLE‐NKCE specifically mediated killing of CεmX‐expressing cells in a dose‐ and effector‐to‐target (E:T) ratio‐dependent manner. The TCE demonstrated robust activity even at low antigen densities and concentrations as low as 1 ng/mL (18 pM). The HLE‐NKCE effectively mediated killing in the presence of human serum albumin, suggesting functionality in physiological conditions. T‐ and NK‐cell activation was observed only in the presence of target cells and TCE. Conclusion: Our novel anti‐CεmX TCE and HLE‐NKCE effectively target and eliminate mIgE‐expressing cells in vitro. Although further investigation is needed, our bispecific engagers are promising off‐the‐shelf therapeutics for the treatment of IgE‐associated allergic diseases.

  • Open Access

    Dose-Reduced FLA-IDA in Combination with Venetoclax Is an Effective and Safe Salvage Therapy in Relapsed and Refractory Acute Myeloid Leukemia (R/R AML)

    by Martin Schönrock, Piet Sonnemann, Nina Michalowski, Michael Heuser, Felicitas Thol, Francis Ayuketang Ayuk, Christine Wolschke, Evgeny Klyuchnikov, Carsten Bokemeyer, Walter Fiedler, et al.

    Background: Despite the development of targeted therapies in first-line AML, complete remissions (CR) cannot be achieved in 30–40%, and relapse rates remain high. In R/R AML the intensive treatment regimen of fludarabine, cytarabine, idarubicin combined with venetoclax (FLA-VIDA) showed improved remission rates compared to FLA-IDA. In this retrospective single-center analysis, we investigated the efficacy and safety of dose-reduced FLA-IDA with and without venetoclax to minimize the risk of infectious complications and excessive myelosuppression; Methods: Between 2011 and 2023, 89 R/R AML patients were treated with dose-reduced FLA-IDA (fludarabine 30 mg/m2 day 1–4, cytarabine 2000 mg/m2 day 1–4, idarubicin 10 mg/m2 day 1 + 4). From 2019 onwards, venetoclax was added (day 1 100 mg, day 2 200 mg, day 3–14 400 mg); Results: Significantly improved response rates were observed with 60.0% vs. 38.8% CR/CRi (p = 0.0297) and 74.5% vs. 47.3% (p = 0.032) CR/CRi/MLFS for FLA-VIDA vs. FLA-IDA. Further, with FLA-VIDA significantly improved event-free survival (EFS) was observed (p = 0.026). Overall survival (OS) was similar in FLA-VIDA and FLA-IDA treated patients. The most common treatment-related toxicities were hematological adverse events, but they were comparable between groups. The time to neutrophil and platelet recovery were similar in responding patients treated with FLA-VIDA vs. FLA-IDA; Conclusions: Dose-reduced FLA-VIDA significantly improved response rates without increases in toxicity, showing promise for an improved R/R AML treatment.